Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Prospective Image Reevaluation Study to Assess the Efficacy of 18F-mFBG PET Imaging in Subjects With Neuroblastoma
Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Summary
This is a prospective image revaluation study designed to assess the performance of 18F-mFBG PET imaging in detecting the presence of neuroblastoma. Eligible participants will have undergone 18F-mFBG PET imaging in a research trial or locally-authorized clinical use and have: a) an established diagnosis of active neuroblastoma; or b) an established diagnosis of neuroblastoma in remission; or c) no history or current evidence of neuroblastoma based on signs, symptoms, imaging findings, and laboratory results.
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
43
Start Date
2026-06-01
Completion Date
2026-08-31
Last Updated
2026-09-22
Healthy Volunteers
Yes
Conditions
Interventions
18F-MFBG
Quantity of 18F-mFBG administered to each subject was determined based on the protocol specifications of the original trial at each participating site. No 18F-mFBG will be administered in this study.
Locations (1)
Innervate Radiopharmaceuticals LLC
Englewood, New Jersey, United States